Highlights from the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, USA, 12–15 May 2001

Key issues discussed at the breast cancer sessions of the 37th American Society of Clinical Oncology (ASCO) meeting, 2001, included the following: breast cancer in the elderly; toxicity; updates on HER2 and use of trastuzumab (anti-HER2) in metastatic disease; and several early reports on novel ther...

Descripción completa

Detalles Bibliográficos
Autor principal: Lohrisch, Caroline
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138698/
http://dx.doi.org/10.1186/bcr320
_version_ 1782120476788654080
author Lohrisch, Caroline
author_facet Lohrisch, Caroline
author_sort Lohrisch, Caroline
collection PubMed
description Key issues discussed at the breast cancer sessions of the 37th American Society of Clinical Oncology (ASCO) meeting, 2001, included the following: breast cancer in the elderly; toxicity; updates on HER2 and use of trastuzumab (anti-HER2) in metastatic disease; and several early reports on novel therapeutic strategies. As was stated by numerous speakers both at this and other meetings, and as demonstrated by several abstracts, the use of predictive factors appears to be the most effective way to enhance the efficacy of numerous therapies, both target specific and nonspecific.
format Text
id pubmed-138698
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1386982003-02-27 Highlights from the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, USA, 12–15 May 2001 Lohrisch, Caroline Breast Cancer Res Meeting Report Key issues discussed at the breast cancer sessions of the 37th American Society of Clinical Oncology (ASCO) meeting, 2001, included the following: breast cancer in the elderly; toxicity; updates on HER2 and use of trastuzumab (anti-HER2) in metastatic disease; and several early reports on novel therapeutic strategies. As was stated by numerous speakers both at this and other meetings, and as demonstrated by several abstracts, the use of predictive factors appears to be the most effective way to enhance the efficacy of numerous therapies, both target specific and nonspecific. BioMed Central 2001 2001-08-10 /pmc/articles/PMC138698/ http://dx.doi.org/10.1186/bcr320 Text en Copyright © 2001 2001 BioMed Central Ltd
spellingShingle Meeting Report
Lohrisch, Caroline
Highlights from the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, USA, 12–15 May 2001
title Highlights from the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, USA, 12–15 May 2001
title_full Highlights from the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, USA, 12–15 May 2001
title_fullStr Highlights from the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, USA, 12–15 May 2001
title_full_unstemmed Highlights from the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, USA, 12–15 May 2001
title_short Highlights from the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, USA, 12–15 May 2001
title_sort highlights from the 37th annual meeting of the american society of clinical oncology, san francisco, usa, 12–15 may 2001
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138698/
http://dx.doi.org/10.1186/bcr320
work_keys_str_mv AT lohrischcaroline highlightsfromthe37thannualmeetingoftheamericansocietyofclinicaloncologysanfranciscousa1215may2001

Ejemplares similares